Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 2, 2009, Pages 171-180

  Grishchenko, Marina ^a   Grieve, Richard D ^b   Sweeting, Michael J ^c,d   De Angelis, Daniela ^c,d   Thomson, Brian J ^e,f   Ryder, Stephen D ^f   Irving, William L ^e,g  

^a Lundbeck   (France)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d MRC BIOSTATISTICS UNIT   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f Department of Medicine ^*

^g QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Antiviral therapy; Chronic hepatitis C; Cost analysis; Decision analytic model; Routine data

Indexed keywords

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; COST ANALYSIS; DECISION-ANALYTIC MODEL; ROUTINE DATA;

AMIDES; ANTIBIOTICS; COST ACCOUNTING; COST EFFECTIVENESS; COSTS; GLYCOPROTEINS; PATIENT TREATMENT;

COST BENEFIT ANALYSIS;

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MODEL; PRACTICE GUIDELINE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; ADULT; COST BENEFIT ANALYSIS; DECISION TREE; DRUG COMBINATION; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MARKOV CHAINS; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN;

EID: 67549093818     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090229     Document Type: Article

References (38)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35-47.
2. Bank of England. Annual average Spot exchange rate. http: //www.bankofengland.co.uk/mfsd/iadb/index.asp?Travel= NIxIRx&levels=1&C= DMD&FullPage=&FullPageHistory= &Nodes=X3790X3791X3873X 33940X3801&SectionRequired= I&HideNums=-1&ExtraInfo= true&E3801XBMX3790- X3791.x=16&E3801XBMX3790X3791.y=5. London: Bank of England; 2007.
3. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
4. Briggs AH. Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol. 2004;16:551-561.
5. British Medical Association. British National Formulary (BNF), No. 54. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; September 2007.
6. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology. 2007;45:579-587. (Pubitemid 46453759)
7. Castelnuovo E, Thompson-Coon J, Pitt M, et al. The costeffectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006;10:iii-iv, ix-xii, 1-93. (Pubitemid 44659285)
8. Curtis L. Unit costs of health and social care 2007. Canterbury, UK: PSSRU Personal Social Services Research Unit; 2007.
9. Dalgard O, Bjøro K, Hellum K et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8:45-49. (Pubitemid 34701984)
10. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective followup study of 384 patients. Gastroenterology. 1997;112:463-472. (Pubitemid 27078833)
11. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(pt 1):809-816. (Pubitemid 32928008)
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
13. Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006;55:1332-1338. (Pubitemid 44277366)
14. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: Arandomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
15. Health Protection Agency. Hepatitis C in England: an update. Annual Report. London: Health Protection Agency; 2006.
16. Longworth L, Bryan S.An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:1061-1067. (Pubitemid 38035310)
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965. (Pubitemid 32913521)
18. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27.
19. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. http://www.nice.org.uk/ media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf; 2008.
20. National Institute for Health and Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. London: NICE; 2004.
21. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. London: NICE; 2006.
22. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196-197. (Pubitemid 32108094)
23. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257-265. (Pubitemid 36286537)
24. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-2100.
25. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut. 2004;53:451-455.
26. Sharma P, Lok A. Viral hepatitis and liver transplantation. Semin Liver Dis. 2006;26:285-297.
27. Shepherd J, Jones J, Hartwell D, et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1-224. (Pubitemid 47207725)
28. Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care. 2005;21:55-65.
29. Sweeting M, De Angelis D, Brant L, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat. 2007 ;14:570-576.
30. Sweeting MJ, De Angelis D, Neal KR, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol. 2006;59:144-152. (Pubitemid 43111618)
31. Tanaka J, Kumada H, Ikeda K, et al. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol. 2003;70:378-386.
32. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: A severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260-1267. (Pubitemid 43829992)
33. Thomson BJ, Kwong G, Ratib S, et al. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat. 2008;15:271-278. (Pubitemid 351326908)
34. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569. (Pubitemid 30729201)
35. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Costeffectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2000;95:1524-1530.
36. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: A cross sectional and longitudinal study. Gut. 2003;52:574-579. (Pubitemid 36363414)
37. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1-113, iii. (Pubitemid 44150878)
38. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724-1732. (Pubitemid 39575851)